Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(e)
Stock Incentive Plan
On May 16, 2017, Curis, Inc. (the Company) held its 2017 Annual Meeting of Stockholders (the Annual Meeting), at
which a quorum was present in person or by proxy.
At the Annual Meeting, the Companys stockholders approved the Companys
Second Amended and Restated 2010 Stock Incentive Plan (the Second Amended and Restated 2010 Plan), which was adopted by the Board of Directors of the Company (the Board) on March 27, 2017, subject to stockholder
approval.
The following summary of the Second Amended and Restated 2010 Plan does not purport to be complete and is qualified in its
entirety by reference to the full text of the Second Amended and Restated 2010 Plan, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Number of Shares Available for Award
Up to 19,000,000 shares of the Companys common stock (subject to adjustment in the event of stock splits and other similar events) may
be issued pursuant to awards granted under the Second Amended and Restated 2010 Plan.
The Second Amended and Restated 2010 Plan uses a
fungible share concept under which each share of stock subject to awards granted as options and stock appreciation rights (SARs), cause one share per share under the award to be removed from the available share pool, while
each share of stock subject to awards granted as restricted stock, restricted stock units, other stock-based awards or performance awards where the price charged for the award is less than 100% of the fair market value of the Companys common
stock will cause 1.3 shares per share under the award to be removed from the available share pool. Shares covered by awards under the Second Amended and Restated 2010 Plan that are forfeited, cancelled or otherwise expire without having been
exercised or settled, or that are settled by cash or other
non-share
consideration, become available for issuance pursuant to a new award and will be credited back to the pool at the same rates described
above. Shares that are tendered or withheld to pay the exercise price of an award or to satisfy tax withholding obligations are not available for issuance pursuant to new awards. Shares are subtracted for exercises of SARs using the proportion of
the total SAR that is exercised, rather than the number of shares actually issued. Shares repurchased by the Company on the open market using proceeds from the exercise of an award will not increase the number of shares available for future grant of
awards.
Types of Awards
The Second Amended and Restated 2010 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the
Internal Revenue Code of 1986 (the Code),
non-statutory
stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards, and cash-based awards as
described below.
Incentive Stock Options and
Non-statutory
Stock
Options
. Optionees receive the right to purchase a specified number of shares of common stock at a specified option price and subject to such other terms and conditions as are specified in connection with the option grant. Options may be granted
only with an exercise price that is equal to or greater than the fair market value of the common stock on the date of grant, provided that if the Companys board approves the grant of an option effective as of a future date, the exercise price
may be not less than 100% of the fair market value on such future date. Under present law, incentive stock options granted to optionees holding more than 10% of the voting power of the Company may not have an exercise price that is less than 110% of
the fair market on the date of grant. No option will provide for the payment or accrual of dividend equivalents. Options may not be granted for a term in excess of ten years (five years in the case of incentive stock options granted to optionees
holding more than 10% of the voting power of the Company). The Second Amended and Restated 2010 Plan permits the following forms of payment of the exercise price of options:
|
|
|
subject to certain conditions, delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax
withholding or delivery by the participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax
withholding;
|
|
|
|
subject to certain conditions, delivery of shares of common stock owned by the participant valued at their fair market value;
|
|
|
|
to the extent provided for in the applicable
non-statutory
stock option agreement or approved by the Board in its sole discretion, by delivery of a notice of net
exercise to the Company;
|
|
|
|
any other lawful means; or
|
|
|
|
any combination of these forms of payment.
|
An option that vests solely based on the passage
of time will not vest earlier than the first anniversary of its date of grant, unless the option is granted in lieu of salary, bonus or other compensation otherwise earned by or payable to the participant. Notwithstanding the foregoing, the Board,
either at the time the option is granted or at any time thereafter, may allow an option to accelerate and become vested, in whole or in part, prior to the first anniversary of its date of grant, if the participants employment by or service to
the Company is terminated under specified circumstances, or in the event of a merger, consolidation, sale, reorganization, recapitalization, or there is a change in control of the Company. No option shall provide for the payment or accrual of
dividend equivalents.
Stock Appreciation Rights.
A stock appreciation right, or SAR, is an award entitling the holder, upon
exercise, to receive an amount in common stock or cash or a combination thereof determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of common stock over the measurement price specified in
the applicable SAR agreement.
The measurement price may not be less than 100% of the fair market value on the date the SAR is granted; provided that if the Board approves the grant of an SAR effective as of a future date, the
measurement price may be not less than 100% of the fair market value on such future date. No SAR will provide for the payment or accrual of dividend equivalents. SARs may not be granted for a term in excess of 10 years. SARs may be granted
independently or in tandem with an option. No SAR shall provide for the payment or accrual of dividend equivalents.
Restricted Stock
Awards.
Awards of restricted stock entitle recipients to acquire shares of common stock, subject to the Companys right to repurchase all or part of such shares from the recipient in the event that the conditions specified in the applicable
award are not satisfied prior to the end of the applicable restriction period established for such award. Any dividends declared and paid by the Company with respect to shares of restricted stock will be paid to the participant only if and when such
shares become free from the restrictions on transferability and forfeitability that apply to such shares.
Restricted Stock Unit
Awards
. Restricted stock unit awards entitle the recipient to receive shares of common stock to be delivered at the time such shares vest (or on a deferred basis) pursuant to the terms and conditions established by the Board. To the extent a
restricted stock unit award provides the recipient with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of common stock (referred to as dividend
equivalents), the Second Amended and Restated 2010 Plan provides that such dividend equivalents must be subject to the same restrictions on transfer and forfeitability as the restricted stock units with respect to which such dividend
equivalents are awarded.
Other Stock-Based Awards.
Under the Second Amended and Restated 2010 Plan, the Board has the right to
grant other awards based upon the common stock having such terms and conditions as the Board may determine, including the grant of shares based upon certain conditions, the grant of awards that are valued in whole or in part by reference to, or
otherwise based on, shares of common stock, and the grant of awards entitling recipients to receive shares of common stock to be delivered in the future. The Board may also grant performance awards or cash-based awards. Any dividends or dividend
equivalents with respect to other stock-based awards, cash-based awards, or performance awards must be subject to the same restrictions on transfer and forfeitability as the award with respect to which such dividend equivalents are awarded.
Performance Conditions.
The compensation committee may determine, at the time of grant, that an award of restricted stock, a restricted
stock unit award, or other stock-based award granted to an officer will vest solely upon the achievement of specified performance criteria designed to qualify for deduction under Section 162(m) of the Code. Performance awards can also provide
for cash payments of up to $1,000,000 per calendar year per individual. The performance criteria for each such award will be based on one or more of the following measures:
|
|
|
the entry into an arrangement or agreement with a third party for the development, commercialization, marketing or distribution of products, services or technologies, or for conducting a research program to discover and
discover and develop a product, service or technology, and/or the achievement of milestones under such arrangement or agreement, including events that trigger an obligation or payment right;
|
|
|
|
the achievement of domestic and international regulatory milestones, including the submission of filings required to advance products, services and technologies in clinical development and the achievement of approvals
by regulatory authorities relating to the commercialization of products, services and technologies;
|
|
|
|
the achievement of discovery, preclinical and clinical stage scientific objectives, discoveries or inventions for products, services and technologies under research and development;
|
|
|
|
the entry into or completion of a phase of clinical development for any product, service or technology, such as the entry into or completion of phase 1, 2 and/or 3 clinical trials;
|
|
|
|
the consummation of debt or equity financing transactions, or acquisitions of business, technologies and assets;
|
|
|
|
new product or service releases;
|
|
|
|
the achievement of qualitative or quantitative performance measures set forth in operating plans approved by the Board from time to time;
|
|
|
|
specified levels of product sales, net income, earnings before or after discontinued operations, interest, taxes, depreciation and/or amortization, operating profit before or after discontinued operations and/or taxes,
sales, sales growth, earnings growth, cash flow or cash position, gross margins, stock price, market share, return on sales, assets, equity or investment, improvement of financial ratings, and
|
|
|
|
achievement of balance sheet or income statement objectives or total stockholder return.
|
Such
goals may reflect absolute entity or business unit performance or a relative comparison to the performance peer group of entities or other external measures of the selected performance criteria and may be absolute in their terms or measured against,
or in relationship to, other companies comparably, similarly or alternatively situated. Such performance goals may be adjusted to exclude any one or more of:
|
|
|
gains or losses on the dispositions of discounted operations;
|
|
|
|
the cumulative effects of changes in accounting principles;
|
|
|
|
the writedown of any asset; and
|
|
|
|
charges for restructuring and rationalization programs.
|
Such performance goals may vary by
participant and may be different for different awards; may be particular to a participant or the department, branch, line of business, subsidiary or other unit in which the participant works and may cover such period as may be specified by the
compensation committee; and will be set by the compensation committee within the time period prescribed by, and will otherwise comply with the requirements of, Section 162(m). The
compensation committee may adjust downwards, but not upwards, the cash or number of shares payable pursuant to such award, and may not waive the achievement of the applicable performance measures except in the case of the participants death or
disability or a change in control.
Transferability of Awards
Except as the Board may otherwise determine or provide in an award, awards may not be sold, assigned, transferred, pledged or otherwise
encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an incentive stock option, pursuant to a qualified domestic relations
order. During the life of the participant, awards are exercisable only by the participant.
Eligibility to Receive Awards
The Companys employees, officers and directors, as well as consultants and advisors to the Company are eligible to be
granted awards under the Second Amended and Restated 2010 Plan. Under present law, however, incentive stock options may only be granted to the Companys employees or those of the Companys present or future parent or subsidiary
corporations.
The maximum number of shares with respect to which awards may be granted to any participant under the Second Amended and
Restated 2010 Plan may not exceed 3,500,000 shares per calendar year. For purposes of this limit, the combination of an option in tandem with an SAR is treated as a single award and each share of common stock subject to an award (including each
share of common stock subject to an award of restricted stock, a restricted stock unit award, other stock-based award or performance award) shall be treated as one share.
Administration
The Second Amended and Restated 2010 Plan is administered by the Board. The Board has the authority to adopt, amend and repeal the
administrative rules, guidelines and practices relating to the Second Amended and Restated 2010 Plan and to interpret the provisions of the Second Amended and Restated 2010 Plan. The Board may construe and interpret the terms of the Second Amended
and Restated 2010 Plan and any award agreements entered into under the Second Amended and Restated 2010 Plan. Pursuant to the terms of the Second Amended and Restated 2010 Plan, the Board may, subject to certain limitations, delegate authority under
the Second Amended and Restated 2010 Plan to one or more committees or subcommittees of the Board. Discretionary awards to
non-employee
directors may be granted and administered only by the Board or a
committee thereof, all of the members of which are independent directors as defined by Section 5605(a)(2) of the NASDAQ Stock Market Marketplace Rules. Subject to certain limitations, the Board may delegate to one or more officers the power to grant
awards and to exercise such other powers under the Second Amended and Restated 2010 Plan as the Board may determine.
Subject to any
applicable limitations contained in the Second Amended and Restated 2010 Plan, the Board or any committee to whom the Board delegates authority, as the case may be, selects the recipients of awards and determines (i) the number of shares of
common stock covered by options and the dates upon which such options become exercisable, (ii) the exercise price of
options (which may not be less than 100% of fair market value of the common stock), (iii) the duration of options (which may not exceed 10 years), and (iv) the number of shares of common
stock subject to any SAR, awards of restricted stock, restricted stock unit award or other stock-based awards and the terms and conditions of such awards, including conditions for repurchase, issue price and repurchase price.
Adjustments for Changes in Common Stock and Certain Other Events
The Board is required to make appropriate adjustments in connection with the Second Amended and Restated 2010 Plan and any outstanding awards
to reflect stock splits, stock dividends, recapitalizations, spin-offs and other similar changes in capitalization. The Second Amended and Restated 2010 Plan also contains provisions addressing the consequences of any Reorganization Event, which is
defined as:
|
|
|
any merger or consolidation of the Company with or into another entity as a result of which all of the Companys common stock is converged into or exchanged for the right to receive cash, securities or other
property, or is cancelled;
|
|
|
|
the Companys liquidation or dissolution.
|
In connection with a Reorganization Event, the
Board or the compensation committee thereof may take any one or more of the following actions as to all or any outstanding awards (other than restricted stock) on such terms as the Board or compensation committee determines:
|
|
|
provide that awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof);
|
|
|
|
upon written notice, provide that all unexercised stock options or other unexercised awards will become exercisable in full and will terminate immediately prior to the consummation of such Reorganization Event unless
exercised within a specified period following the date of such notice;
|
|
|
|
provide that outstanding awards will become realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part prior to or upon such Reorganization Event;
|
|
|
|
in the event of a Reorganization Event under the terms of which holders of the Companys common stock will receive, upon consummation thereof, a cash payment for each share surrendered in the Reorganization Event
(the Acquisition Price), make or provide for a cash payment to an award holder equal to (i) the Acquisition Price times the number of shares of the Companys common stock subject to the holders awards (to the extent the
exercise price does not exceed the Acquisition Price) minus (ii) the aggregate exercise price of all the holders outstanding awards, in exchange for the termination of such awards;
|
|
|
|
provide that, in connection with a liquidation or dissolution of the Company, awards will convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof); and
|
|
|
|
any combination of the foregoing.
|
Upon the occurrence of a Reorganization Event other than a
liquidation or dissolution, the Companys repurchase and other rights with respect to outstanding restricted stock shall inure to the benefit of the Companys successor and shall, unless the Board determines otherwise, apply to the cash,
securities or other property which the common stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to such restricted stock; provided, however, that the Board may
provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any restricted stock or any other agreement between the Company and a Second Amended and Restated 2010 Plan participant, either
initially or by amendment. Upon the occurrence of a Reorganization Event involving a liquidation or dissolution, except to the extent specifically provided to the contrary in the instrument evidencing any restricted stock, all restrictions and
conditions on all restricted stock then outstanding shall automatically be deemed terminated or satisfied.
Unless otherwise provided for
in the instrument evidencing any stock option or any other agreement between the Company and a Second Amended and Restated 2010 Plan participant, effective immediately prior to a Change in Control Event (as this term is defined in the
Second Amended and Restated 2010 Plan), the vesting schedule of all options and awards of restricted stock then outstanding shall be accelerated in part so that
one-half
of the number of shares that would
otherwise have first become vested and/or free from restrictions and conditions on any date after the date of the Change in Control Event shall immediately become exercisable. The remaining
one-half
of such
number of shares shall continue to become vested in accordance with the original vesting schedule set forth in such option or award of restricted stock, with
one-half
of the number of shares that would
otherwise have become vested and/or free from restrictions and conditions on each subsequent vesting date in accordance with the original schedule becoming vested on each such subsequent vesting date; provided, however, that each such option and
award of restricted stock shall be immediately exercisable in full and/or free from restrictions and conditions if, on or prior to the first anniversary of the date of the consummation of the Change in Control Event, the participants
employment with the Company or the Acquiring Corporation (as this term is defined in the Second Amended and Restated 2010 Plan) is terminated for Good Reason (as this term is defined in the Second Amended and Restated 2010 Plan) by the participant
or is terminated without Cause (as this term is defined in the Second Amended and Restated 2010 Plan) by the Company or the Acquiring Corporation.
The Board may specify in an award at the time of grant the effect of a Change in Control Event on an SAR or other stock-based award.
Except as described above, the Board or the compensation committee thereof may at any time provide that any award will become immediately
exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be. However, if any participant terminates his or her employment with the Company due to the
participants death or disability, all awards held by the participant will automatically become fully vested, exercisable, or realizable.
If any award expires or is terminated, surrendered, canceled or forfeited, the unused shares of
the Companys common stock covered by such award will again be available for grant under the Second Amended and Restated 2010 Plan, subject, in the case of incentive stock options, to any limitations under the Code.
Substitute Awards
In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity,
the Board may grant awards in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute awards may be granted on such terms as the Board deems appropriate in the circumstances,
notwithstanding any limitations on awards contained in the Second Amended and Restated 2010 Plan. Substitute awards will not count against the overall share limit or any sublimits under the Second Amended and Restated 2010 Plan, except as may be
required by the Code.
Restrictions on Repricing
Unless the Companys stockholders approve such action (or it is appropriate under a change in capitalization, a reorganization event, or a
Change in Control Event), the Second Amended and Restated 2010 Plan provides that the Company may not:
|
|
|
amend any outstanding stock option or SAR granted under the Second Amended and Restated 2010 Plan to provide an exercise price per share that is lower than the then-current exercise or measurement price per share of
such outstanding award;
|
|
|
|
cancel any outstanding option or SAR (whether or not granted under the Second Amended and Restated 2010 Plan) and grant in substitution therefor new awards under the Second Amended and Restated 2010 Plan (other than as
substitute awards as described above) covering the same or a different number of shares of common stock and having an exercise or measurement price per share lower than the then-current exercise or measurement price per share of the cancelled award;
|
|
|
|
cancel for cash any options or SARs that then have exercise or measurement prices per share below the fair market value of the Companys common stock; or
|
|
|
|
take any other action that constitutes a repricing within the meaning of the rules of the NASDAQ Stock Market.
|
Provisions for Foreign Participants
The Board or the compensation committee thereof may modify awards granted to participants who are foreign nationals or employed outside the
United States, or establish subplans or procedures under the Second Amended and Restated 2010 Plan to recognize differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee
benefit or other matters.
Amendment or Termination
No Award may be made under the Second Amended and Restated 2010 Plan after June 3, 2020 but awards previously granted may extend beyond
that date. The Board may at any time amend, suspend or terminate the Second Amended and Restated 2010 Plan; provided that, to the extent determined by the Board, no amendment requiring stockholder approval under any applicable legal, regulatory or
listing requirement, including amendments with regard to the prohibition on repricing or the minimum vesting provisions, will become effective until such stockholder approval is obtained.
Subject to certain limitations, the Board may amend, modify or terminate any outstanding award, including but not limited to, substituting
therefor another award of the same or a different type, changing the date of exercise or realization, and converting an incentive stock option to a
non-statutory
stock option.
2017 Short Term Incentive Plan
On
May 18, 2017, the compensation committee of the Board approved its annual short-term cash incentive plan for executive officers for the 2017 fiscal year (the 2017 Short Term Incentive Plan). The 2017 Short Term Incentive Plan is
designed to motivate the Companys executive officers to achieve specified performance objectives for the 2017 fiscal year and to reward them upon achievement of those objectives.
Eligibility
. The compensation committee has determined that as of the date of the adoption of the 2017 Short Term Incentive Plan, the
following executive officers are eligible to participate in the program: Ali Fattaey, Ph.D., President and Chief Executive Officer, James E. Dentzer, Chief Financial Officer and Chief Administrative Officer, Mani Mohindru, Ph.D., Senior Vice
President and Chief Strategy Officer and David Tuck, M.D., Senior Vice President and Chief Medical Officer.
Administration
. The
compensation committee will administer the 2017 Short Term Incentive Plan. The compensation committee has the authority and discretion to modify performance goals under the 2017 Short Term Incentive Plan and has the right to amend, modify or
terminate the 2017 Short Term Incentive Plan at any time.
Awards
. The compensation committee has established the following
short-term incentive payment amounts (the Target Amounts), for each executive officer:
|
|
|
|
|
|
|
|
|
|
|
|
|
Designated
Executive Officer
|
|
2017 Annual Base
Salary
|
|
|
Target Incentive Compensation
Payment as a Percentage of 2017
Annual Base Salary,
Assuming
Performance at the 100% Level
|
|
Ali Fattaey, Ph.D.
|
|
$
|
590,000
|
|
|
|
60
|
%
|
|
$
|
354,900
|
|
|
|
|
|
James E. Dentzer
|
|
$
|
442,900
|
|
|
|
40
|
%
|
|
$
|
177,160
|
|
|
|
|
|
David Tuck, M.D.
|
|
$
|
420,000
|
|
|
|
40
|
%
|
|
$
|
168,000
|
|
|
|
|
|
Mani Mohindru, Ph.D.
|
|
$
|
405,000
|
|
|
|
35
|
%
|
|
$
|
141,750
|
|
The compensation committee has established weighted categories of corporate goals for 2017
pertaining to execution of certain clinical program objectives and certain financial objectives. Each of the weighted categories has been further delineated into three levels of potential achievement: Threshold; Target; and
Maximum. Cash incentive payments may be paid based upon the degree to which each category of corporate goals has been achieved on this continuum, if at all. For each of the categories, achievement of performance at the
Threshold level results in a weighted payment of no less than 50% of the target amount set forth above, achievement of performance at the Target level results in a weighted payment equal to 100% of the target amount set forth
above, and achievement of performance at the Maximum level results in a weighted payment of no more than 150% of the target amount set forth above.
Distribution
. The awards generally will be paid in cash. The compensation committee has sole discretion, however, to pay an award using
a combination of cash and equity or all equity, with any such equity being issued pursuant to the Second Amended and Restated 2010 Stock Incentive Plan. If the compensation committee determines that such payment will be made in whole or in part in
the form of equity, the compensation committee shall have the sole discretion to determine the nature, amount and other terms of such equity award. Payment of the awards, if any, will be made after the completion of fiscal year 2017 and no later
than March 15, 2018.